{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:31:56Z","timestamp":1793673116506,"version":"4.5.1"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.lungcan.2022.05.011","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T19:14:23Z","timestamp":1653160463000},"page":"41-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":147,"special_numbering":"C","title":["Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies"],"prefix":"10.1016","volume":"170","author":[{"given":"Melissa","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Chiara","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Mitsudomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2022.05.011_b0005","doi-asserted-by":"crossref","unstructured":"J. Greenhalgh, K. Dwan, A. Boland, V. Bates, F. Vecchio, Y. Dundar, P. Jain, J.A. Green, First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer, Cochrane Database Syst Rev (5) (2016) Cd010383.","DOI":"10.1002\/14651858.CD010383.pub2"},{"issue":"5","key":"10.1016\/j.lungcan.2022.05.011_b0010","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/j.cllc.2019.05.003","article-title":"Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort","volume":"20","author":"Lau","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.lungcan.2022.05.011_b0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ctrv.2018.06.018","article-title":"Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer","volume":"69","author":"Sharma","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"48","key":"10.1016\/j.lungcan.2022.05.011_b0020","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.011_b0025","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.18632\/oncotarget.13815","article-title":"Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions","volume":"8","author":"Kuan","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.lungcan.2022.05.011_b0030","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1183\/09031936.00014009","article-title":"Pathogenesis of lung cancer signalling pathways: roadmap for therapies","volume":"33","author":"Brambilla","year":"2009","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2022.05.011_b0035","doi-asserted-by":"crossref","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.lungcan.2022.05.011_b0040","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3390\/cancers6020708","article-title":"The Role of STAT3 in Non-Small Cell Lung Cancer","volume":"6","author":"Harada","year":"2014","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2022.05.011_b0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan","year":"2019","journal-title":"Signal Transduct. Target Ther."},{"issue":"2","key":"10.1016\/j.lungcan.2022.05.011_b0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1753465815617871","article-title":"Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches","volume":"10","author":"Shea","year":"2016","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"4","key":"10.1016\/j.lungcan.2022.05.011_b0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nature Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2022.05.011_b0060","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2022.05.011_b0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.011_b0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated,EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2022.05.011_b0075","doi-asserted-by":"crossref","first-page":"e0223530","DOI":"10.1371\/journal.pone.0223530","article-title":"First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis","volume":"14","author":"Zhang","year":"2019","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.lungcan.2022.05.011_b0080","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.lungcan.2022.05.011_b0085","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1158\/0008-5472.CAN-19-0024","article-title":"CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC","volume":"79","author":"Becker","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.011_b0090","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1038\/ncomms10690","article-title":"Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells","volume":"7","author":"Ramirez","year":"2016","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.lungcan.2022.05.011_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071590","article-title":"Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations","volume":"10","author":"Suda","year":"2021","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.lungcan.2022.05.011_b0100","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.011_b0105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2022.05.011_b0110","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2022.05.011_b0115","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2022.05.011_b0120","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"issue":"6","key":"10.1016\/j.lungcan.2022.05.011_b0125","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.lungcan.2022.05.011_b0130","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"21","key":"10.1016\/j.lungcan.2022.05.011_b0135","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-06-1570","article-title":"Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors","volume":"12","author":"Balak","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.lungcan.2022.05.011_b0140","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-08-0151","article-title":"Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma","volume":"14","author":"Bean","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2022.05.011_b0145","doi-asserted-by":"crossref","unstructured":"D.B. Costa, S.T. Schumer, D.G. Tenen, S. Kobayashi, Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations, J Clin Oncol 26(7) (2008) 1182-4; author reply 1184-6.","DOI":"10.1200\/JCO.2007.14.9039"},{"issue":"75","key":"10.1016\/j.lungcan.2022.05.011_b0150","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2022.05.011_b0155","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3892\/ol.2013.1705","article-title":"Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-naive patient: A report of three cases","volume":"7","author":"Yamaguchi","year":"2014","journal-title":"Oncol. Lett."},{"issue":"10","key":"10.1016\/j.lungcan.2022.05.011_b0160","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1078-0432.CCR-07-2248","article-title":"Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer","volume":"14","author":"Engelman","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2022.05.011_b0165","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.05.011_b0170","doi-asserted-by":"crossref","first-page":"viii740","DOI":"10.1093\/annonc\/mdy424.063","article-title":"Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2022.05.011_b0175","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.21037\/jtd.2019.08.32","article-title":"Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"12","author":"Chen","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2022.05.011_b0180","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2016.11.008","article-title":"EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance","volume":"385","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"issue":"24","key":"10.1016\/j.lungcan.2022.05.011_b0185","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-1542","article-title":"Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC","volume":"24","author":"Le","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.lungcan.2022.05.011_b0190","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.011_b0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jtho.2019.11.005","article-title":"The evolving landscape of resistance to osimertinib","volume":"15","author":"Schoenfeld","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2022.05.011_b0200","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation","volume":"2","author":"Takezawa","year":"2012","journal-title":"Cancer Discov."},{"issue":"13","key":"10.1016\/j.lungcan.2022.05.011_b0205","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients","volume":"24","author":"Yang","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2022.05.011_b0210","doi-asserted-by":"crossref","first-page":"e000060","DOI":"10.1136\/esmoopen-2016-000060","article-title":"Mechanisms of resistance to EGFR-targeted drugs: lung cancer","volume":"1","author":"Morgillo","year":"2016","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.011_b0215","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1159\/000513904","article-title":"Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report","volume":"14","author":"Blasi","year":"2021","journal-title":"Case Rep. Oncol."},{"issue":"5827","key":"10.1016\/j.lungcan.2022.05.011_b0220","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"issue":"2005","key":"10.1016\/j.lungcan.2022.05.011_b0225","first-page":"0008","article-title":"Phosphotyrosine interactome of the ErbB-receptor kinase family","volume":"1","author":"Schulze","year":"2005","journal-title":"Mol. Syst. Biol."},{"issue":"6","key":"10.1016\/j.lungcan.2022.05.011_b0230","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.31891","article-title":"Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies","volume":"125","author":"Ahn","year":"2019","journal-title":"Cancer"},{"issue":"suppl_1","key":"10.1016\/j.lungcan.2022.05.011_b0235","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2022.05.011_b0240","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.jtho.2018.05.027","article-title":"Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors","volume":"13","author":"Schrock","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.011_b0245","first-page":"140","article-title":"Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation, Thorac","volume":"11","author":"Hayakawa","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2022.05.011_b0250","first-page":"188","article-title":"Transformation to small cell lung cancer after first-line afatinib treatment","volume":"23","author":"Shiroyama","year":"2018","journal-title":"Respir. Med. Case Rep."},{"issue":"10","key":"10.1016\/j.lungcan.2022.05.011_b0255","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2022.05.011_b0260","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.05.011_b0265","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2019.04.014","article-title":"Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer","volume":"132","author":"Park","year":"2019","journal-title":"Lung Cancer"},{"issue":"18","key":"10.1016\/j.lungcan.2022.05.011_b0270","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2006.10.4166","article-title":"Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib","volume":"25","author":"Cho","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2022.05.011_b0275","first-page":"1975","article-title":"Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer","volume":"34","author":"Horiike","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lungcan.2022.05.011_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.2100","article-title":"Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","author":"Papadimitrakopoulou","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.05.011_b0285","doi-asserted-by":"crossref","first-page":"11815","DOI":"10.1038\/ncomms11815","article-title":"Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients","volume":"7","author":"Chabon","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2022.05.011_b0290","doi-asserted-by":"crossref","unstructured":"D.S. Ettinger, D.E. Wood, D.L. Aisner, W. Akerley, J. Bauman, L.R. Chirieac, T.A. D'Amico, M.M. DeCamp, T.J. Dilling, M. Dobelbower, R.C. Doebele, R. Govindan, M.A. Gubens, M. Hennon, L. Horn, R. Komaki, R.P. Lackner, M. Lanuti, T.A. Leal, L.J. Leisch, R. Lilenbaum, J. Lin, B.W. Loo, Jr., R. Martins, G.A. Otterson, K. Reckamp, G.J. Riely, S.E. Schild, T.A. Shapiro, J. Stevenson, S.J. Swanson, K. Tauer, S.C. Yang, K. Gregory, M. Hughes, Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw 15(4) (2017) 504-535.","DOI":"10.6004\/jnccn.2017.0050"},{"key":"10.1016\/j.lungcan.2022.05.011_b0295","doi-asserted-by":"crossref","unstructured":"D. Planchard, S. Popat, K. Kerr, S. Novello, E.F. Smit, C. Faivre-Finn, T.S. Mok, M. Reck, P.E. Van Schil, M.D. Hellmann, S. Peters, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol 29(Suppl 4) (2018) iv192-iv237.","DOI":"10.1093\/annonc\/mdy275"},{"issue":"36","key":"10.1016\/j.lungcan.2022.05.011_b0300","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1200\/JCO.2017.73.9250","article-title":"Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses","volume":"35","author":"Mok","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.05.011_b0305","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.2147\/OTT.S143569","article-title":"Continuous EGFR tyrosine kinase inhibitor treatment with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients","volume":"10","author":"Peng","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"3","key":"10.1016\/j.lungcan.2022.05.011_b0310","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/annonc\/mdv597","article-title":"Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib\/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial","volume":"27","author":"Schuler","year":"2016","journal-title":"Ann. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2022.05.011_b0315","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.21037\/atm.2016.09.45","article-title":"Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question?","volume":"4","author":"Bhateja","year":"2016","journal-title":"Ann Transl Med"},{"issue":"12","key":"10.1016\/j.lungcan.2022.05.011_b0320","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.lungcan.2022.05.011_b0325","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jtho.2018.05.015","article-title":"Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC","volume":"13","author":"Gettinger","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.lungcan.2022.05.011_b0330","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2022.05.011_b0335","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jtho.2019.02.001","article-title":"Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report","volume":"14","author":"Yang","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.lungcan.2022.05.011_b0340","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1158\/1078-0432.CCR-21-3194","article-title":"A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)","volume":"28","author":"Hayashi","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.lungcan.2022.05.011_b0345","doi-asserted-by":"crossref","first-page":"e1356145","DOI":"10.1080\/2162402X.2017.1356145","article-title":"EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer","volume":"6","author":"Dong","year":"2017","journal-title":"Oncoimmunology"},{"issue":"18","key":"10.1016\/j.lungcan.2022.05.011_b0350","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.lungcan.2022.05.011_b0355","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/annonc\/mdx183","article-title":"Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment","volume":"28","author":"Haratani","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.05.011_b0360","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-2027","article-title":"Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer","author":"Isomoto","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2022.05.011_b0365","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2018.09.010","article-title":"Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer","volume":"125","author":"Liu","year":"2018","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2022.05.011_b0370","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/j.jtho.2018.09.012","article-title":"Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations","volume":"13","author":"Toki","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2022.05.011_b0375","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review","volume":"112","author":"Brody","year":"2017","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2022.05.011_b0380","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/1759-7714.13346","article-title":"Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC","volume":"11","author":"Ishii","year":"2020","journal-title":"Thorac Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2022.05.011_b0385","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2022.05.011_b0390","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.4049\/jimmunol.177.10.6780","article-title":"T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine","volume":"177","author":"Kobie","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.lungcan.2022.05.011_b0395","doi-asserted-by":"crossref","first-page":"CT163","DOI":"10.1158\/1538-7445.AM2021-CT163","article-title":"CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b\/2 study [abstract]","volume":"81","author":"Kim","year":"2021","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.011_b0400","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41392-021-00813-y","article-title":"First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence","volume":"6","author":"Hafner","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.011_b0405","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40880-019-0414-4","article-title":"The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)","volume":"39","author":"Zhang","year":"2019","journal-title":"Cancer Commun (Lond)"},{"issue":"5","key":"10.1016\/j.lungcan.2022.05.011_b0410","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"24","key":"10.1016\/j.lungcan.2022.05.011_b0415","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.lungcan.2022.05.011_b0420","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2022.05.011_b0425","doi-asserted-by":"crossref","unstructured":"K. Nakagawa J.C.H. Yang K. Park Y. Ohe Y.L. Wu J. Gainor A. Blackwood-Chirchir R. Yang I.F. Chang T. Mok 481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy Annals of Oncology 27 2016 ix154-ix155.","DOI":"10.1016\/S0923-7534(21)00639-6"},{"key":"10.1016\/j.lungcan.2022.05.011_b0430","first-page":"13","article-title":"ORIENT-31 as the Sakigake \u201cCharging Samurai\u201d Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the \u201cMeiji Modernization\u201d of Post-3G EGFR TKI Progression?","volume":"13","author":"Nagasaka","year":"2022","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.lungcan.2022.05.011_b0435","unstructured":"S. Lu, et al. ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy. Presented as the ESMO Asia Virtual Plenary Session on November 19, 2021."},{"issue":"2","key":"10.1016\/j.lungcan.2022.05.011_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.xinn.2021.100103","article-title":"Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors","volume":"2","author":"Du","year":"2021","journal-title":"The Innovation"},{"issue":"3","key":"10.1016\/j.lungcan.2022.05.011_b0445","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.pharmthera.2013.12.014","article-title":"The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance","volume":"142","author":"Maroun","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"Suppl_9","key":"10.1016\/j.lungcan.2022.05.011_b0450","doi-asserted-by":"crossref","first-page":"ix177","DOI":"10.1093\/annonc\/mdy483.007","article-title":"Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study","volume":"29","author":"Cho","year":"2018","journal-title":"Ann. Oncol."},{"issue":"Suppl_8","key":"10.1016\/j.lungcan.2022.05.011_b0455","doi-asserted-by":"crossref","first-page":"viii741","DOI":"10.1093\/annonc\/mdy424.064","article-title":"Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","volume":"29","author":"Papadimitrakopoulou","year":"2018","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2022.05.011_b0460","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40265-020-01347-3","article-title":"Capmatinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.lungcan.2022.05.011_b0465","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2217\/fon-2021-1406","article-title":"INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance","volume":"18","author":"Smit","year":"2022","journal-title":"Future Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2022.05.011_b0470","doi-asserted-by":"crossref","first-page":"e000063","DOI":"10.1136\/esmoopen-2016-000063","article-title":"Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib","volume":"1","author":"Azuma","year":"2016","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.lungcan.2022.05.011_b0475","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol."},{"issue":"30","key":"10.1016\/j.lungcan.2022.05.011_b0480","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2022.05.011_b0485","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-021-01561-7","article-title":"Amivantamab: First Approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.lungcan.2022.05.011_b0490","doi-asserted-by":"crossref","unstructured":"E.B. Haura, C.C. Byoung, J.S. Lee, J.Y. Han, K.H. Lee, R.E. Sanborn, JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC), J Clin Oncol 37(15_suppl) (2019) 9009-9009.","DOI":"10.1200\/JCO.2019.37.15_suppl.9009"},{"key":"10.1016\/j.lungcan.2022.05.011_b0495","doi-asserted-by":"crossref","unstructured":"J. Bauml B.C. Cho K. Park K.H. Lee E.K. Cho D.-W. Kim S.-W. Kim E.B. Haura J.K. Sabari R.E. Sanborn M. Nagasaka S.-H.-I. Ou A.R. Minchom J.E. Gomez J.C. Curtin G. Gao A. Roshak M. Thayu R.E. Knoblauch A.I. Spira Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-na\u00efve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response Journal of Clinical Oncology 39 15_suppl 2021 9006 9006.","DOI":"10.1200\/JCO.2021.39.15_suppl.9006"},{"issue":"16","key":"10.1016\/j.lungcan.2022.05.011_b0500","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazieres","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.011_b0505","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13046-017-0653-7","article-title":"Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines","volume":"36","author":"La Monica","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.011_b0510","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-18-1590","article-title":"Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy","volume":"25","author":"Peters","year":"2019","journal-title":"Safety, and Biomarkers, Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.lungcan.2022.05.011_b0515","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial","volume":"36","author":"Li","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.05.011_b0520","series-title":"Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion","author":"Tsurutani","year":"2020"},{"issue":"3","key":"10.1016\/j.lungcan.2022.05.011_b0525","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2022.05.011_b0530","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.jtho.2021.01.285","article-title":"OA04.05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01","volume":"16","author":"Nakagawa","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"2","key":"10.1016\/j.lungcan.2022.05.011_b0535","first-page":"142","article-title":"High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas","volume":"10","author":"Yi","year":"1997","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.011_b0540","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jss.2007.05.030","article-title":"ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers","volume":"146","author":"Kawano","year":"2008","journal-title":"J. Surg. Res."},{"issue":"7","key":"10.1016\/j.lungcan.2022.05.011_b0550","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/onc.2015.142","article-title":"Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib","volume":"35","author":"Yonesaka","year":"2016","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.lungcan.2022.05.011_b0555","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-016-3231-3","article-title":"Phase 1 study of new formulation of patritumab (U3\u20131287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer","volume":"79","author":"Shimizu","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"23","key":"10.1016\/j.lungcan.2022.05.011_b0560","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1158\/1078-0432.CCR-19-1745","article-title":"A Novel HER3-Targeting Antibody-Drug Conjugate, U3\u20131402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization","volume":"25","author":"Hashimoto","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.011_b0565","first-page":"74","article-title":"Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"EGFR-Mutated Non-Small Cell Lung Cancer, Cancer Discov"},{"key":"10.1016\/j.lungcan.2022.05.011_b0570","series-title":"Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate","author":"Okajima","year":"2021"},{"issue":"2","key":"10.1016\/j.lungcan.2022.05.011_b0575","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3892\/ol.2013.1368","article-title":"Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma","volume":"6","author":"Jiang","year":"2013","journal-title":"Oncol Lett"},{"key":"10.1016\/j.lungcan.2022.05.011_b0580","doi-asserted-by":"crossref","first-page":"S1283","DOI":"10.1016\/j.annonc.2021.08.2128","article-title":"LBA49 - Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced\/metastatic (adv\/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study","volume":"32","author":"Garon","year":"2021","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2022.05.011_b0585","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab Govitecan: First Approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.lungcan.2022.05.011_b0590","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1358\/dot.2018.55.9.3039669","article-title":"Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors","volume":"55","author":"Fenn","year":"2019","journal-title":"Drugs Today (Barc)"},{"issue":"17","key":"10.1016\/j.lungcan.2022.05.011_b0595","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.lungcan.2022.05.011_b0600","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2022.05.011_b0605","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-018-0778-0","article-title":"Third generation EGFR TKIs: current data and future directions","volume":"17","author":"Tan","year":"2018","journal-title":"Mol Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2022.05.011_b0610","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","article-title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors","volume":"5","author":"Huang","year":"2015","journal-title":"Acta Pharm Sin B"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022200441X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022200441X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:00:38Z","timestamp":1759237238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022200441X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":121,"alternative-id":["S016950022200441X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.05.011","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}